Incyclinide (BioDeep_00000837988)

   


代谢物信息卡片


Incyclinide

化学式: C19H17NO7 (371.1004972)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1C2CC3=C(C(=CC=C3)O)C(=C2C(=O)C4(C1CC(=O)C(=C4O)C(=O)N)O)O
InChI: InChI=1S/C19H17NO7/c20-18(26)14-11(22)6-9-5-8-4-7-2-1-3-10(21)12(7)15(23)13(8)16(24)19(9,27)17(14)25/h1-3,8-9,21,23,25,27H,4-6H2,(H2,20,26)/t8-,9-,19-/m0/s1

描述信息

C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C1970 - Matrix Metalloproteinase Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor

同义名列表

1 个代谢物同义名

Incyclinide



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Bing He, Lana Garmire. Prediction of repurposed drugs for treating lung injury in COVID-19. F1000Research. 2020; 9(?):609. doi: 10.12688/f1000research.23996.2. [PMID: 32934806]
  • Hairong Song, Mona Fares, Kim R Maguire, Ake Sidén, Zuzana Potácová. Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cells. PloS one. 2014; 9(12):e114457. doi: 10.1371/journal.pone.0114457. [PMID: 25502932]
  • Xiaomin Yang, Lin Zhao, Laszlo Almasy, Vasil M Garamus, Aihua Zou, Regine Willumeit, Saijun Fan. Preparation and characterization of 4-dedimethylamino sancycline (CMT-3) loaded nanostructured lipid carrier (CMT-3/NLC) formulations. International journal of pharmaceutics. 2013 Jun; 450(1-2):225-34. doi: 10.1016/j.ijpharm.2013.04.021. [PMID: 23608200]
  • Shreyas K Roy, Brian D Kubiak, Scott P Albert, Christopher J Vieau, Louis Gatto, Lorne Golub, Hsi-Ming Lee, Suraj Sookhu, Yoram Vodovotz, Gary F Nieman. Chemically modified tetracycline 3 prevents acute respiratory distress syndrome in a porcine model of sepsis + ischemia/reperfusion-induced lung injury. Shock (Augusta, Ga.). 2012 Apr; 37(4):424-32. doi: 10.1097/shk.0b013e318245f2f9. [PMID: 22258231]
  • Ying Gu, Hsi-Ming Lee, Timo Sorsa, Aino Salminen, Maria E Ryan, Marvin J Slepian, Lorne M Golub. Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation. Pharmacological research. 2011 Dec; 64(6):573-9. doi: 10.1016/j.phrs.2011.06.023. [PMID: 21771657]
  • Xiaoqin Zhou, Dongfang Wang, Cherry K Ballard-Croft, Sanford R Simon, Hsi-Ming Lee, Joseph B Zwischenberger. A tetracycline analog improves acute respiratory distress syndrome survival in an ovine model. The Annals of thoracic surgery. 2010 Aug; 90(2):419-26. doi: 10.1016/j.athoracsur.2010.04.052. [PMID: 20667323]
  • Julia Cazalis, Shin-ichi Tanabe, Guy Gagnon, Timo Sorsa, Daniel Grenier. Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood. Inflammation. 2009 Apr; 32(2):130-7. doi: 10.1007/s10753-009-9111-9. [PMID: 19238528]
  • Bruce J Dezube, Susan E Krown, Jeannette Y Lee, Kenneth S Bauer, David M Aboulafia. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Mar; 24(9):1389-94. doi: 10.1200/jco.2005.04.2614. [PMID: 16549833]
  • Jay Steinberg, Jeffrey Halter, Henry Schiller, Louis Gatto, David Carney, Hsi-Ming Lee, Lorne Golub, Gary Nieman. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock (Augusta, Ga.). 2005 Oct; 24(4):348-56. doi: 10.1097/01.shk.0000180619.06317.2c. [PMID: 16205320]
  • Subir R Maitra, Marc J Shapiro, Sikha Bhaduri, M Raafat El-Maghrabi. Effect of chemically modified tetracycline on transforming growth factor-beta1 and caspase-3 activation in liver of septic rats. Critical care medicine. 2005 Jul; 33(7):1577-81. doi: 10.1097/01.ccm.0000169880.82060.f7. [PMID: 16003065]
  • Michelle A Rudek, Carol Hartke, Yelena Zabelina, Ming Zhao, Pamela New, Sharyn D Baker. A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection. Journal of pharmaceutical and biomedical analysis. 2005 Apr; 37(4):751-6. doi: 10.1016/j.jpba.2004.10.052. [PMID: 15797797]
  • Jing Li, Shufeng Zhou, Hung Huynh, Eli Chan. Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline. Pharmaceutical research. 2005 Mar; 22(3):397-404. doi: 10.1007/s11095-004-1877-8. [PMID: 15835745]
  • Samira Syed, Chris Takimoto, Manuel Hidalgo, Jinee Rizzo, John G Kuhn, Lisa A Hammond, Garry Schwartz, Anthony Tolcher, Amita Patnaik, S Gail Eckhardt, Eric K Rowinsky. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Oct; 10(19):6512-21. doi: 10.1158/1078-0432.ccr-04-0804. [PMID: 15475438]
  • Jing Li, Hung Huynh, Eli Chan. Reversed-phase liquid chromatography method to determine COL-3, a matrix metalloproteinase inhibitor, in biological samples. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004 Jan; 799(2):311-21. doi: 10.1016/j.jchromb.2003.10.066. [PMID: 14670750]
  • Michelle A Rudek, Jürgen Venitz, Yuichi Ando, Eddie Reed, James M Pluda, William D Figg. Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. Journal of clinical pharmacology. 2003 Oct; 43(10):1124-35. doi: 10.1177/0091270003256675. [PMID: 14517195]
  • Subir R Maitra, Sikha Bhaduri, Patrick D Valane, Taina Tervahartiala, Timo Sorsa, Nungavarm Ramamurthy. Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock (Augusta, Ga.). 2003 Sep; 20(3):280-5. doi: 10.1097/00024382-200309000-00014. [PMID: 12923502]
  • Yu-Luan Chen, Glenn D Hanson, Naidong Weng, Christopher Powala, Brad Zerler. Quantification of 6-deoxy-6-demethyl-4-dedimethylaminotetracycline (COL-3) in human plasma using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Aug; 794(1):77-88. doi: 10.1016/s1570-0232(03)00419-7. [PMID: 12888200]
  • Jing Li, Hung Huynh, Eli Chan. Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration. Pharmaceutical research. 2002 Nov; 19(11):1655-62. doi: 10.1023/a:1020901328583. [PMID: 12458671]
  • D Grenier, P Plamondon, T Sorsa, H M Lee, T McNamara, N S Ramamurthy, L M Golub, O Teronen, D Mayrand. Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives. Journal of periodontology. 2002 Jan; 73(1):79-85. doi: 10.1902/jop.2002.73.1.79. [PMID: 11846203]
  • Mary Cianfrocca, Timothy P Cooley, Jeannette Y Lee, Michelle A Rudek, David T Scadden, Lee Ratner, James M Pluda, William D Figg, Susan E Krown, Bruce J Dezube. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Jan; 20(1):153-9. doi: 10.1200/jco.2002.20.1.153. [PMID: 11773164]
  • Y Gu, H M Lee, E J Roemer, L Musacchia, L M Golub, S R Simon. Inhibition of tumor cell invasiveness by chemically modified tetracyclines. Current medicinal chemistry. 2001 Feb; 8(3):261-70. doi: 10.2174/0929867013373642. [PMID: 11172681]
  • J Chen, M Bookbinder, M E Ryan, L M Golub, R Ashley, N S Ramamurthy. Biodistribution of radiolabeled [(3)H] CMT-3 in rats. Current medicinal chemistry. 2001 Feb; 8(3):253-6. doi: 10.2174/0929867013373615. [PMID: 11172679]
  • M A Rudek, W D Figg, V Dyer, W Dahut, M L Turner, S M Steinberg, D J Liewehr, D R Kohler, J M Pluda, E Reed. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Jan; 19(2):584-92. doi: 10.1200/jco.2001.19.2.584. [PMID: 11208854]
  • M A Rudek, C L March, K S Bauer, J M Pluda, W D Figg. High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma. Journal of pharmaceutical and biomedical analysis. 2000 Jul; 22(6):1003-14. doi: 10.1016/s0731-7085(00)00257-0. [PMID: 10857569]
  • J T Bettany, R G Wolowacz. Tetracycline derivatives induce apoptosis selectively in cultured monocytes and macrophages but not in mesenchymal cells. Advances in dental research. 1998 Nov; 12(2):136-43. doi: 10.1177/08959374980120010901. [PMID: 9972138]